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Abstract
Background: S. pneumoniae is the leading cause of acute bacterial meningitis (ABM) in children. Vaccination using
the 10-valent conjugate vaccine (PCV-10) was recently introduced into the National Immunization Program in
Mozambique, but data on serotype coverage of this vaccine formulation are scarce. In this study, we investigated
the serotype distribution and antimicrobial resistance of isolates of S. pneumoniae causing ABM in children < 5 years
at the two largest hospitals in Mozambique.
Methods: Between March 2013 and March 2014, a total of 352 cerebrospinal fluid (CSF) samples were collected
from eligible children, of which 119 (33.8 %) were positive for S. pneumoniae. Of these, only 50 samples met the
criteria for serotyping and were subsequently serotyped using sequential multiplex PCR (SM-PCR), but 15 samples were
non-typable.
Results: The most common serotypes of S. pneumoniae were 1 (18.2 %), 5 (15.2 %), 14 (12.1 %), 9 V (12.1 %), 23 F (9.
1 %), 6A (9.1 %), 4 (9.1 %) and 6B (6.1 %). Serotypes 1, 5, 9 V, 6A and 12 were mostly prevalent in Northern
Mozambique, while serotypes 23 F, 4, 6B, 3 and 15B were predominant in Southern. Serotype coverage of PCV-10 and
PCV-13 vaccine formulations were 81.8 % and 93.9 %, respectively. Serotypes 1, 3, 4, 6B, 14, 23 F were resistant to
penicillin and sensitive to ceftriaxone.
Conclusions: Our findings shows that changing the current in use PCV-10 vaccine formulation to PCV-13
formulation might increase substantially the protection against invasive strains of S. pneumoniae as the PCV-10
vaccine formulation does not cover the serotypes 3 and 6A, which are prevalent in Mozambique.
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Background
Streptococcus pneumoniae is the leading cause of otitis
media, sinusitis, bacteremia, pneumonia, meningitis and
sepsis in children. Worldwide, an estimated 1.6 million
of children under the age of 5 die every year as a conse-
quence of S. pneumoniae related diseases [1–3]. The elderly
and immunosuppressed individuals are also vulnerable [4].
Meningitis is a serious consequence of invasive disease
caused by S. pneumoniae, leading to more than 100,000
deaths annually in children under the age of 5 [2, 3].
Recent estimates demonstrate that up to 90 % of these
deaths occurs in resource-limited settings, mostly in
sub-Saharan Africa and Asia [3, 5].
Pneumococcus is an antigenically complex bacteria and
currently, more than 95 serotypes have been described
[6–8]. These serotypes differ in term of pathogenesis, tar-
get organ, age, geographical distribution, virulence and
susceptibility to antibiotics [9].
Globally, the most common serotypes are 1, 5, 14, 6A,
6B, 19 F and 23 F, of which serotypes 1, 5, 6A and 14 occur
predominantly in developing countries, whereas serotypes
19 F, 6B, 23 F and 14 occur mostly in developed countries
[10, 11]. In recent years, the rapid spread of antimicrobial
resistant S. pneumoniae strains and the emergence of
multidrug-resistant strains (MDRSP), has increased the
global concern for pneumococcal infection [12].
In regard to Mozambique, data on serotype distribu-
tion of S. pneumoniae are scarce, and with the exception
of one study conducted in Manhiça district, a rural area
in southern Mozambique [13], no other study has yet
been conducted. Therefore, data from Manhiça district
has few limitations, such as, they are more than 10 years
old and, taken into consideration that Manhiça is a rural
village, these data are difficult to generalize to the entire
country given the size and geographic diversity of
Mozambique, particularly in terms of climate, demo-
graphic, socio-economic and cultural aspects [14]. In
this regard, it is possible that serotype distribution and
antimicrobial sensitivity of S. Pneumoniae may vary in
different regions of the country. This is particularly
important in a time in which Mozambique recently
introduced the PCV-10 vaccine formulation into the
Extended Program of Immunization.
In this context, this study was conducted with the
purpose of determining the frequency and distribution
of capsular serotypes of S. pneumoniae causing acute
bacterial meningitis in children under 5 years of age at
the two largest hospitals in the country, Maputo Central
Hospital, in the Southern region, and Nampula Central
Hospital, in the Northern region of the country. This
study will generate information on the serotype coverage
of pneumococcal conjugate vaccine formulations and
present baseline data for future assessments of the
impact of pneumococcal vaccination in Mozambique.
Methods
Study design, study sites and target population
This study was implemented as part of the routine
sentinel surveillance system for pediatric acute bacterial
meningitis (ABM), implemented by the National Insti-
tute of Health (INS) in Mozambique. The sentinel
surveillance system for ABM was established in March
2013 at two regional hospitals, Maputo Central Hospital
(HCM) and Nampula Central Hospital (HCN). Both are
regional referral hospitals and offer several specialized
medical services, including inpatient and outpatient care
across all age groups.
The HCN is situated in Nampula province, the most
populous in the country, has 23 districts with a total of
3,985,613 inhabitants [14]. The paediatric ward at HCN
has 184 beds. The HCM is situated in Maputo city, the
capital of Mozambique, with a total of 1,766,823 inhabi-
tants [14]. HCM is the largest hospital in the country,
with 322 beds in the paediatric ward. All children admit-
ted to these health facilities with clinical presentation of
ABM between March 2013 and March 2014 were
eligible for enrolment.
Case definition
Per WHO guidelines, suspected case of ABM is defined
as a child aged < 5 years with sudden onset of fever
(>38.5 °C rectal or 38.0 °C axillary) and at least 1 of the
following signs: neck stiffness or flaccid neck, bulging
fontanel, convulsion, irritability, or drowsiness.
Samples collection and questionnaire
Upon admission, lumbar puncture (LP) was aseptically
performed by a trained pediatrician on each child who
met the case definition for ABM.
A standard case investigation form was used to collect
clinical and demographic data.
Laboratory testing
Bacteriological testing of CSF samples at sentinel site
As part of routine surveillance for ABM, cerebrospinal
fluid (CSF) samples were initially cultured at the senti-
nel sites onto 5 % sheep blood agar plates (MAST,
Merseyside, UK) and all growing isolates were stored
between 2-8 °C and shipped to the National Reference
Microbiology Laboratory (NRML) in Maputo for fur-
ther testing.
Identification of S. pneumoniae by culture at NRML
At the NRML, all isolates received from the sentinel site
were frozen at -80 °C until further testing. Isolates were
recovered by plating onto 5 % sheep blood and chocolate
agar plates (MAST, Merseyside, UK). Twenty-four hours
after incubation at 35 ° C ±2 ° C with 5 % of CO2,
bacterial isolates were identified by colony morphologic
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analysis and growth requirement. Pneumococci were
identified based on morphological features in Gram stain,
optochin susceptibility test (OXOID – DD1 OPTOCHIN,
Basingstoke, England) and bile solubility (BD – BBL
Desoxycholate Reagent Droppers, Becton Dickinson and
Company, USA) [15]. All isolates of S. pneumoniae, were
used for molecular serotyping.
DNA extraction from CSF samples and S. pneumoniae isolates
Two hundred microliters of all CSF samples and isolates
of S. pneumoniae previously identified by culture were
used for DNA extraction. DNA was extracted using
either Biopour mini kit (BIOPUR, Biometrix diagnostic,
Brazil), or High pure PCR template kit (Roche Diagnostics
Corporation, US), according to the manufacturer’s instruc-
tions. Total DNA was eluted in 200 μl of appropriated
elution buffer and stored at −20 °C until use.
Diagnosis of S. pneumoniae using PCR
Molecular diagnosis of S. pneumoniae was performed as
part of the routine diagnosis of meningitis within the
national surveillance system for pediatric ABM, imple-
mented by the National Institute of Health. Routinely, the
molecular diagnosis of meningitis is performed using M-
qPCR. This assay was based on SYBER detection system
(Platinum SYBR Green qPCR Supermix-UDG, Invitrogen,
California, UK) using the LightCycler 2.0 instrument
(Roche Diagnostic GmbH, Mannheim, Germany). This
detects simultaneously Neisseria meningitidis, Streptococ-
cus pneumoniae, and Haemophilus influenzae using a set
of specific primers as described by Ke et al., 2000 [16];
Corless et al., 2001[17] and El Aila et al., 2011 [18].
Serotyping of S. pneumoniae
Serotyping was performed on all isolates of S. pneumo-
niae and all CSF samples from PCR positive children,
whose cycle threshold (ct) value was lower than 30. CSF
samples from PCR positive children whose ct value was
higher than 30, were excluded, due to insufficient DNA
for serotyping. Serotyping was performed using the Se-
quential multiplex PCR (SM-PCR), adapted for regional
algorithm, and covering the 39 most common serotypes
involved in the etiology of invasive pneumococcal dis-
eases (IPD) in Africa, and grouped into 8 multiplex PCR
reactions [19]. The capsular polysaccharide (cps) was
used as internal control. The reaction was performed
in a final volume of 25 μl. Each reaction mix con-
tained buffer solution at 2x, 0.2 mM concentration of
each deoxynucleoside triphosphate (dNTPs), reaction
buffer 10x (100 mM of Tris-HCl, pH 8.5 and
500 mM of KCl), 1.7 mM of MgCl2, 1.5U⁄ μl of Taq
DNA polymerase, primers at the concentration from
0.1 to 0.5 uM and 5 μl of template DNA. The PCR
assays were performed in a thermocycler (GeneAmp
PCR System 9700, PE Applied Biosystems). Samples
were amplified as follows: an initial denaturation step
at 95 °C for 15 min, followed by 35 cycles at 95 °C
for 30 seconds (denaturation), 54 °C for 90 seconds
(annealing) and 72 °C for 1 min (elongation). After
amplification, PCR products were analyzed by gel
electrophoresis.
Antimicrobial susceptibility test
Minimum inhibitory concentrations (MICs) to penicillin,
erythromycin, vancomycin, trimethoprim-sulfamethoxazole,
tetracycline and ceftriaxone were determined using E-test®
(Biomereux, SA) strips. The results were interpreted ac-
cording to Clinical and Laboratory Standards Institute
guidelines (CLSI, 2014) [20]. The reference strain S.
pneumoniae ATCC 49619 was used as the quality control.
Statistical analysis
Data were entered into a database developed using Epi
Info version 3.5.4 (CDC U.S.A.) and was analyzed using
SPSS statistical software version 20 (IBM, U.S.A.). Cat-
egorical variables were reported as proportion and statis-
tical significance differences were assessed using Pearson
Chi-square test with a significance level of less than 0.05.
Results
General characteristics of study participants
Between March 2013 and March 2014, a total of 352
CSF samples were collected from children clinically
suspected of ABM who were admitted to two referral
hospitals. The median age of study participants was
9 months (IQR 4 - 30 months) and 52.8 % (186/352) of
them were male. More than half of the children were
aged less than 12 months, while children of the age
group 12-23 months and 24-59 months comprised 11 %
(39/352) and 31 % (109/352) of the study group (Table 1).
Children from Nampula Central Hospital, represented
73.6 % from the sample (n = 259), while children from
Maputo Central Hospital represented 26.4 % (n = 93).
Children from HCM and HCN were similar in term of
their age (median: 17.4 months for HCN and 20.3 months
for HCN, respectively) and gender (male gender = 51.6 %
in HCM and 53.3 % in HCN, respectively). S. pneumoniae
was identified in a total of 119 (33.8 %) samples, of
which 17 were initially identified by culture and the
remaining 102 were identified by PCR. Serotyping for
S. pneumoniae using SM-PCR was performed in a
total of 50 samples, comprising the 17 isolates of S.
pneumoniae identified by culture and 33 PCR positive
CSF samples for which their ct value was inferior to
30. Most of children with positive result for S. pneu-
moniae and children with typable CSF sample were
aged below 12 months, following the same pattern of
enrolled children (Table 1).
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Serotype distribution and coverage rate of pneumococcal
vaccine formulations
Of the 50 samples for which serotyping was performed,
a total of 33 (66.0 %) were typable and their correspond-
ing serotype was identified, the remaining 17 samples
were not-typeable (SM-PCR NT), as shown in Fig. 1.
The most frequent serotypes were 1 (18.2 %, 6/33),
5 (15.2 %, 5/33), 14 (12.1 %, 4/33), 9 V (12.1 %, 4/33), 23 F
(9.1 %, 3/33), 6A (9.1 %, 3/33), 4 (9.1 %, 3/33), 6B (6.1 %,
2/33), 12 (3.0 %, 1/33), 15B (3 %, 1/33) and 3 (3.0 %, 1/33).
Table 1 Age and gender distribution of enrolled patients, patients with positive and negative CSF results and patients with typable
CSF samples
Characteristics Total (n = 352) S. pneumoniae positive (n = 119) Children with typable CSF (n = 33)
Age
0-11 months 204 (58.0 %) 77 (64.7 %) 24 (72.7 %)
12-23 months 39 (11.0 %) 18 (15.1 %) 3 (9.1 %)
24-59 months 109 (31.0 %) 24 (20.2 %) 6 (18.2 %)
Gender
Male 186 (52.8 %) 66 (55.5 %) 13 (39.4 %)
Female 166 (47.2 %) 53 (44.5 %) 20 (60.6 %)
Fig. 1 Flowchart of sample collection and testing. The flow chart depicts the number of CSF samples collected from of children under 5 years
old at each sentinel site and tested at sentinel site and NMRL between March 2013 and study March 2014. Abbreviations. CSF: Cerebrospinal
fluid; HCM: Hospital Central de Maputo; HCN: Hospital Central de Nampula; SM-PCR: sequential multiplex polymerase chain reaction; NMRL:
National Reference Microbiology Laboratory
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Serotype distribution of children older than 2 years old
was significantly different of that of children younger than
2 years old (Chi-Square = 28; p = 0.001).
Figure 2 shows that the rate of vaccine coverage
against the serotypes of S. pneumoniae causing pediatric
meningitis in Mozambique was 48.5 % (16/33), 81.8 %
(27/33), and 93.9 % (31/33) for PCV-7, PCV-10, and
PCV-13, respectively.
The serotypes 1, 5, 9 V, 6A and 12 were mostly found
in Northern Mozambique, while serotypes 23 F, 4, 6B,
3 and 15B were reported mostly in the Southern
Mozambique (Fig. 3). In addition, the non-PCV-10
serotype 3 and 15B (frequency of 3.0 % for both iso-
lates) were found in Maputo city, situated in southern
Mozambique, while the non-PCVs serotype 12 (frequency
of 3.0 %) was found in Nampula city, situated in northern
part of the country.
Antimicrobial susceptibility profile of isolates of
S. pneumoniae
Table 2 summarises the antibiotic susceptibility profile
of pneumococcal serotypes, and showed that 88.2 %
of serotypes were resistant to penicillin (MIC > 0.
125 μg/mL), according to the revised CLSI break-
points for parenteral penicillin (resistant ≥ 0.12 mg/mL
for meningitis isolates), while for ceftriaxone all sero-
types were susceptible (100 %). The susceptibility rate
for erythromycin, vancomycin, chloramphenicol and
tetracycline were 76.5 %, 88.2 % and 64.7 %, 35.3 %,
respectively.
Discussion
In this study we described for the first time the serotype
distribution of S pneumoniae at the two largest hospitals
in Mozambique, and provided baseline data for further
assessments of the impact of pneumococcal vaccination.
Findings from our study show that in Mozambique,
the predominant serotypes of S. pneumoniae causing
ABM in children aged <5 year were 1, 5, 14, 9 V, 23 F,
6A and 4. This finding is similar to a recent study
conducted in South Africa [21], but is different than that
reported in studies conducted in Nigeria [22] Burkina
Faso and Togo, which found that serotypes 14, 1 and 18
were the most prevalent [23].
Of note, our data suggests that the distribution S.
pneumoniae serotypes in the Northern differs of that in
the Southern, as shown in the Fig. 3. However, these
findings should be interpreted with caution because of
the small size of our sample, which is not representative
of the entire population in the country. Studies with
larger size should be conducted to confirm these results.
In regard to serotype coverage of PCV-10, data from
our study show that this vaccine formulation covers
81.8 % (27/33) of S. pneumoniae strains identified in this
study. Similar results were found in a previous study
conducted in Manhiça District, a rural community situ-
ated in southern Mozambique [13], South Africa [21],
and other sub-Saharan countries situated in the African
meningitis belt, such as Burkina Faso, Togo [24, 25] and
Nigeria [22]. Our data show that PCV-13 vaccine formu-
lation would increase the serotype coverage from the
current 81.8 %, to 93.9 % because PCV-13 formulation
Fig. 2 Distribution of serotypes of S. pneumoniae and vaccine coverage rates for PCV-7, PCV-10 and PCV-13 vaccine formulations. Each bar
represents the relative frequency of each serotype of S. pneumoniae. The value in the arrows above the bars depicts the vaccine coverage rates
for PCV-7, PCV-10 and PCV-13, respectively NV, serotypes not included in 13-valent pneumococcal conjugate vaccine. NV, nonvaccine serotypes
(serotypes 12 and 15B)
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provide added protection against the serotypes 3, 6A
and 19A.
Our results also show that serotype 1 was the most com-
mon cause of pneumococcal meningitis in Mozambique,
which is in agreement with findings from other Sub-
Saharan Africa countries [13, 22, 24]. The high prevalence
of serotype 1 might be a consequence of a previous epi-
demics caused by this serotype in Mozambique, as has been
reported in other settings, such as Ghana [10].
Additionally, data from our study show that serotype 3
occurs in children, although with low frequency. This is
relevant because serotype 3 is an important cause of
invasive disease in children [9] and has been associated
with high fatality rates [26, 27].
Serotypes 12 and 15B, known as non-vaccine serotypes
(NV) occurred in 6 % of the children. This is an import-
ant finding, because these serotypes are not included in
the existing PCVs vaccine formulations. Similar findings
were reported in studies conducted in South Africa and
other sub-Saharan Africa countries [21, 28].
In regards to antimicrobial susceptibility profile, resist-
ance of S. pneumoniae to penicillin was high, but this
result cannot be generalized due to the small number of
isolates tested in this study. This finding is in agreement
with previous studies, which also suggest that the rate of
resistance of S. pneumoniae to penicillin and other
antibiotic classes is increasing [29–34]. Resistance to
penicillin was also observed for serotypes 1, 3, 4, 6B, 14,
23 F. These results are similar to those reported in
recent studies conducted in South Africa [21], Algeria
[33] and China [35].
An important finding of this study was the fact that two
S. pneumoniae strains belonging to serotype 6A presented
a decreased susceptibility to vancomycin (MIC = 1.52 μg/
Fig. 3 Distribution of serotypes of S. pneumoniae stratified by region, between March 2013 and March 2014. Figure depicts the distribution of
S. pneumoniae serotypes in the southern (HCM) and northern (HCN). Each color represents one serotype
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mL, for both). Our results corroborate finding from a re-
cent study conducted by Ataee et al, 2014 in Iran, which
reported emergence of vancomycin tolerant, strains of S.
pneumoniae. In his report, Ataee et al, 2014 found that
8 % (4/46) of S. pneumoniae strains presented a lower
susceptibility to vancomycin as measured by assessment
of MIC [36]. In fact, the number of studies reporting the
emergence of meningitis caused by S. pneumoniae strains
that are tolerant to vancomycin is increasing [37, 38].
These patients have been shown to have a poorer survival
rate than patients with meningitis caused by nontolerant
strains [37, 38]. Another study conducted by Sanaei et al
found that among S. pneumoniae carrier’s children, the
proportion of S. pneumoniae strains resistant to vancomicin
was 1.5 % [39]. Altogether, this represents an important
warning that vancomycin resistant or tolerant strains of S.
pneumoniae are emerging as a serious public health threats.
We found that 17 out of 50 isolates were not-typeable.
The reasons why these samples were not-typeable are
unknown, however, molecular serotyping as it’s consid-
ered the gold standard method for serotyping. Moreover,
multiplex PCR has been shown to be more accurate in
determining the serotype of S. penumoniae as compared
to serological methods [22, 40]. In term of sensitivity of
this method, our sequential multiplex PCR (SM-PCR),
was adapted for regional algorithm, and covers the 39
most common serotypes involved in the etiology of
invasive pneumococcal diseases (IPD) in Africa. We
argue that emerging isolates in Africa belonging to some
other serotypes, not covered by the 39 serotypes scheme
may be present and would need further consideration.
To our knowledge, this is the first description of
S. pneumonieae serotype distribution in Northern
Mozambique.
We would like to acknowledge some limitations of our
study, which may influence the interpretation of the
results and extrapolation to the entire population. For
example, the relatively small size of our sample, in
particular from Maputo Central Hospital might have
influenced our results and findings, in particular, the
number of strains used for determining the antibiotic
susceptibility rate was very small. In addition, the infor-
mation was incomplete in several of the standard case
investigation forms such as vaccination status.
Conclusion
Our study provides preliminary findings on serotype
distribution of S. pneumoniae causing ABM in Southern
and Northern Mozambique showing that the serotype
coverage of the recently introduced PCV-10 vaccine
formulation against the serotypes of S. pneumoniae
circulating in Mozambique is 81.8 %, as opposed to the
coverage of 93.9 % if we were using PCV-13 vaccine
formulation, suggesting that changing from the currently
in use PCV-10 formulation to PCV-13 can save
additional lives. Lower coverage of PCV-10 is attributed
to the emergence of non-PCV-10 serotypes 3 and 6A.
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Table 2 Antibiotic susceptibility profile of S. pneumoniae serotypes
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PEN (n/N) ERY (n/N) SXT (n/N) VANC (n/N) CRO (n/N) TCY (n/N) CHL (n/N)
Ra R R R R R R
14 4 4/4 1/4 4/4 0/4 0/4 3/4 0/4
6A 2 2/2 0/2 2/2 2/2 0/2 2/2 2/2
4 2 2/2 1/2 2/2 0/2 0/2 1/1 1/2
3 1 1/1 0/1 1/1 0/1 0/1 1/1 0/1
1 1 1/1 0/1 1/1 0/1 0/1 0/1 0/1
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aResistant
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